A cross-sectional study was performed of pediatric hematology-oncology pati
ents who received vancomycin; use was compared to the Centers for Disease C
ontrol and Prevention (CDC) recommendations for vancomycin use. Thirty-seve
n patients received 308 doses of vancomycin. All patients initially receive
d vancomycin as empirical therapy; 100% of this use was not consistent with
the CDC recommendations (Infect Central Hosp Epidemiol 2000; 21:48-50).